Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

FPCPD
83358
PLHBB
9096
4. Orfao A, Garcia-Sanz R, Lopez-Berges MC, et al: A new method for the analysis of plasma cell DNA
content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
Cytometry 1994 Dec 1;17(4):332-339 5. Morice WG, Hanson CA, Kumar S, et al: Novel multi-parameter
flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative
disorders. Leukemia 2007 Sep;21(9):2043-2046 6. Morice WG, Chen D, Kurtin PJ, et al: Novel
immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with
Waldenstrom's macroglobulinemia. Mod Pathol 2009 Jun;22(6):807-816
Plasma Cell Proliferative Disorder (PCPD), FISH
Clinical Information: Multiple myeloma is a hematologic neoplasm that generally originates in the
bone marrow and develops from malignant plasma cells. There are 4 main categories of plasma cell
proliferative disorders (PCPDs): asymptomatic myeloma, smoldering myeloma, indolent myeloma, and
multiple myeloma. Asymptomatic myeloma patients have nonspecific symptoms that may be attributed
to other diseases. Generalized bone pain, anemia, numbness or limb weakness, symptoms of
hypercalcemia, and recurrent infections are all symptoms that may indicate myeloma. In smoldering
myeloma there is a monoclonal protein spike, but it is stable. Indolent myeloma is a slowly progressing
myeloma. As myeloma progresses, the malignant plasma cells interfere with normal blood product
formation in the bone marrow resulting in anemia and leukopenia. Myeloma also causes an
overstimulation of osteoclasts, causing excessive breakdown of bone tissue without the normal
corresponding bone formation. These bone lesions are seen in approximately 66% of myeloma patients.
In advanced disease, bone loss may reach a degree where the patient suffers fractures easily.
Useful For: Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell
proliferative disorders Identifying prognostic markers based on the anomalies found
Interpretation: A neoplastic clone is detected when the percent of cells with an abnormality exceeds
the normal reference range for any given probe.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Fonseca R, Blood E, Rue M, et al: Clinical and biologic implications of
recurrent genomic aberrations in myeloma. Blood 2003 Jun 1;101(11):4569-4575 2. Fonseca R, Blood
EA, Oken MM, et al: Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique
subset of patients. Blood 2002 May 15;99(10):3735-3741 3. Shaughnessy J, Tian E, Sawyer J, et al:
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase
FISH. Blood 2000 Aug 15;96(4):1505-1511
Plasma Hemoglobin, Plasma
Clinical Information: Plasma normally contains no free hemoglobin ie, no hemoglobin that is not
contained in erythrocytes. Significant amounts of hemoglobin occur in plasma following hemolysis
such as might result from a transfusion reaction or mechanical fragmentation of red blood cells during
cardiac surgery.
Useful For: Determining whether hemolysis is occurring such as from: -Transfusion reaction
-Mechanical fragmentation of red blood cells
Interpretation: Total hemoglobin: > or =12 months: 0.0-15.2 mg/dL Reference values have not been
established for patients who are less than 12 months of age. Oxyhemoglobin: > or =12 months: 0.0-12.4
mg/dL Reference values have not been established for patients who are less than 12 months of age.
Reference Values:
TOTAL HEMOGLOBIN
> or =12 months: 0.0-15.2 mg/dL
Reference values have not been established for patients who are less than 12 months of age.
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1435